IONIS PHARMACEUTICALS INC - COMMON STOCK (IONS)

Historical Holders from Q4 2015 to Q3 2025

Symbol
IONS on Nasdaq
Type / Class
Equity / COMMON STOCK
Shares outstanding
159M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
168M
Holdings value
$11B
% of all portfolios
0.014%
Grand Portfolio weight change
+0%
Number of holders
427
Number of buys
243
Number of sells
-156
Average Value change %
+0%
Average buys %
+0.005%
Average sells %
-0.004%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of IONIS PHARMACEUTICALS INC - COMMON STOCK (IONS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 10.43% $490M 16.5M The Vanguard Group 31 Dec 2024
T. Rowe Price Investment Management, Inc. 8.3% -17% $861M -$176M 13.2M -17% T. Rowe Price Investment Management, Inc. 30 Sep 2025
Capital World Investors 7.3% $341M 11.5M Capital World Investors 31 Dec 2024
BlackRock, Inc. 5.7% $270M 9.07M BlackRock, Inc. 31 Mar 2025
WELLINGTON MANAGEMENT GROUP LLP 4.3% $284M 6.88M Wellington Management Group LLP 30 Jun 2025

Institutional Holders of IONIS PHARMACEUTICALS INC - COMMON STOCK (IONS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 168M $11B +$32M $65.42 427
2025 Q2 169M $6.67B +$163M $39.51 360
2025 Q1 166M $5B +$132M $30.17 340
2024 Q4 160M $5.61B +$73.8M $34.96 348
2024 Q3 157M $6.3B +$510M $40.06 348
2024 Q2 143M $6.82B +$50.2M $47.66 353
2024 Q1 142M $6.15B -$14.8M $43.35 355
2023 Q4 142M $7.21B +$87.4M $50.59 360
2023 Q3 140M $6.34B +$143M $45.36 307
2023 Q2 137M $5.6B +$218M $41.03 299
2023 Q1 131M $4.69B +$26.8M $35.74 307
2022 Q4 131M $4.94B +$160M $37.77 333
2022 Q3 126M $5.59B -$405M $44.23 335
2022 Q2 125M $4.61B +$7.65M $37.02 329
2022 Q1 125M $4.62B +$93.8M $37.04 314
2021 Q4 123M $3.75B +$12.5M $30.43 321
2021 Q3 122M $4.08B -$99.8M $33.54 306
2021 Q2 124M $4.96B +$72M $39.89 321
2021 Q1 123M $5.54B +$78.8M $44.96 347
2020 Q4 120M $6.79B +$106M $56.54 366
2020 Q3 119M $5.62B -$83.6M $47.45 353
2020 Q2 120M $7.08B +$119M $58.96 364
2020 Q1 118M $5.58B -$142M $47.28 346
2019 Q4 121M $7.3B -$83.5M $60.41 378
2019 Q3 122M $7.3B -$290M $59.91 359
2019 Q2 127M $8.13B +$1.22B $64.27 384
2019 Q1 117M $9.52B -$556K $81.17 381
2018 Q4 118M $6.36B -$40.8M $54.06 313
2018 Q3 118M $6.1B +$13.1M $51.58 309
2018 Q2 118M $4.93B +$130M $41.67 298
2018 Q1 115M $5.07B +$57M $44.08 316
2017 Q4 114M $5.72B -$67.8M $50.30 308
2017 Q3 115M $5.84B +$171M $50.70 295
2017 Q2 112M $5.68B +$50.5M $50.87 286
2017 Q1 111M $4.46B +$334M $40.20 265
2016 Q4 109M $5.2B +$130M $47.83 300
2016 Q3 106M $3.89B -$67M $36.64 268
2016 Q2 109M $2.54B +$41.6M $23.29 270
2016 Q1 105M $4.26B +$20.9M $40.50 305
2015 Q4 103M $6.39B +$6.39B $61.93 328